Inhibition of melanoma growth and metastasis by ATF2-derived peptides

Cancer Research

Volumn 64, Issue 22, 2004, Pages 8222-8230

  Bhoumik, Anindita ^a   Gangi, Lisa ^b   Ronai, Ze'ev ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 7 HYDROXYSTAUROSPORINE; ACTIVATING TRANSCRIPTION FACTOR 2; CASPASE 9; HYBRID PROTEIN; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING SITE; CANCER INHIBITION; CANCER REGRESSION; CARCINOGENICITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME DEGRADATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ACTIVATING TRANSCRIPTION FACTOR 2; ANIMALS; APOPTOSIS; CELL DIVISION; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; HUMANS; MELANOMA; MICE; MICE, NUDE; NEOPLASM METASTASIS; PEPTIDES; SKIN NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 8544259596     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0714     Document Type: Article

References (35)

1. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-51.
2. Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene 2003;22:3152-61.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature (Lond) 2002;417:949-54.
4. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003;104:527-32.
5. Ronai Z, Yang YM, Fuchs SY, et al. ATF2 confers radiation resistance to human melanoma cells. Oncogene 1998;16:523-31.
6. Bar-Eli M. Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res 2001;14:78-85.
7. Ivanov VN, Krasilnikov M, Ronai Z. Regulation of Fas expression by STAT3 and c-Jun is mediated by phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 2002;277:4932-44.
8. Ivanov VN, Bhoumik A, Krasilnikov M, et al. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell 2001;7:517-28.
9. Ivanov VN, Fodstad O, Ronai Z. Expression of ring finger-deleted TRAF2 sensitizes metastatic melanoma cells to apoptosis via up-regulation of p38, TNF alpha and suppression of NF-kappaB activities. Oncogene 2001;20:2243-53.
10. Newman JR, Keating AE. Comprehensive identification of human bZIP interactions with coiled-coil arrays. Science (Wash DC) 2003;300:2097-101.
11. Steinmuller L, Cibelli G, Moll JR, Vinson C, Theil G. Regulation and composition of activator protein 1 (AP-1) transcription factors controlling collagenase and c-Jun promote activities. Biochem J 2001;360:599-607.
12. Kaszubska W, Hooft van Huijsduijnen R, Ghersa P, et al. Cyclic AMP-independent ATF family members interact with NF-kappa B and function in the activation of the E-selectin promoter in response to cytokines. Mol Cell Biol 1993;13:7180-90.
13. Kim SJ, Wagner S, Liu F, et al. The retinoblastoma gene product activates expression of the human TGF-beta 2 gene through transcription factor ATF-2. Nature (Lond) 1992;358:331-4.
14. Ouwens DM, de Ruiter ND, van der Zon GC, et al. Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-p38. EMBO J 2002;21:3782-93.
15. Gupta S, Campbell D, Derijard B, Davis RJ. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science (Wash DC) 1995;267:389-93.
16. Bhoumik A, Ivanov V, Ronai Z. Activating transcription factor 2-derived peptides alter resistance of human tumor cell lines to ultraviolet irradiation and chemical treatment. Clin Cancer Res 2001;2:331-42.
17. Bhoumik A, Huang TG, Ivanov V, et al. An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastases. J Clin Investig 2002;110:643-50.
18. Bhoumik A, Jones N, Ronai Z. Sensitization of melanoma to apoptosis by ATF2-derived peptide depends on its association with JNK, activation of JunD and inhibition of ATF2 transcriptional activities. Proc Natl Acad Sci USA 2004;101:4222-7.
19. Vocero-Akbani A, Lissy NA, Dowdy SF. Transduction of full-length Tat fusion proteins directly into mammalian cells: analysis of T cell receptor activation-induced cell death. Methods Enzymol 2000;322:508-21.
20. Ivanov VN, Ronai Z. Down-regulation of tumor necrosis factor alpha expression by activating transcription factor 2 increases UVC-induced apoptosis of late-stage melanoma cells. J Biol Chem 1999;274:14079-89.
21. Macaulay VM, Salisbury AJ, Bohula EA, et al. Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene 2001;20:4029-40.
22. Kanter-Lewensohn L, Dricu A, Wang M, et al. Expression of the insulin-like growth factor-1 receptor and its antiapoptic effect in malignant melanoma: a potential therapeutic target. Melanama Res 1998;8:389-97.
23. Belardelli F, Ciolli V, Testa U, et al. Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors. Int J Cancer 1989;44:1108-16.
24. Singer JD, Gurian-West M, Clurman B, Roberts JM. Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. Genes Dev 1999;13:2375-87.
25. Winston JT, Chu C, Harper JW. Culprits in the degradation of cyclin E apprehended. Genes Dev 1999;13:2751-7.
26. Yamazaki H, Nakata T, Okada Y, Hirokawa N. Cloning and characterizing of KAP3: a novel kinesin superfamily-associated protein of KIF3A/3B. Proc Natl Acad Sci USA 1996;93:8443-8.
27. Manning BD, Snyder M. Drivers and passengers wanted! The role of kinesin-associated proteins. Trends Cell Biol 2000;10:281-9.
28. Mashima T, Udagawa S, Tsuruo T. Involvement of transcriptional repressor ATF3 in acceleration of caspase protease activation during DNA damaging agent-induced apoptosis J Cell Physiol 2001;188:352-8.
29. Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Investig Dermatol 2000;115:337-44.
30. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004;10:39-49.
31. Czaja MJ, Weiner FR, Freedman JH. Amplification of the metallothionein-1 and metallothionein-2 genes in copper-resistant hepatoma cells. J Cell Physiol 1991;147:434-8.
32. Lapierre LA, Kumar R, Hales CM, et al. Myosin vb is associated with plasma membrane recycling systems. Mol Biol Cell 2001;12:1843-57.
33. Kang D, Jiang H, Wu Q, Pestka S, Fisher PB. Cloning and characterization of human ubiquitin-processing protease-43 from terminally differentiated human melanoma cells using rapid subtraction hybridization protocol RaSH. Gene 2001;267:233-42.
34. Kallunki T, Deng T, Hibi M, Karin M. c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 1996;87:929-39.
35. Weiss C, Schneider S, Wagner EF, et al. JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun. EMBO J 2003;22:3686-95.